Is childhood physical and sexual abuse a significant predictor of suicide risk in veterans? This article examined this question and found the best predictors of suicide in this population. Read on to find out more.
Clinical Practice Guidelines have been published by the US military to aid in clinical management of patients with PTSD. To investigate whether these best-practice guidelines are being followed, this population-based study, covering a 7-year period, is the first to describe prescribing patterns for active duty service members diagnosed with PTSD.
Ketamine has shown promise in treating depression and posttraumatic stress disorder (PTSD) individually. This article examines repeated ketamine infusions for individuals with comorbid treatment-resistant depression and PTSD—read it to learn how efficacious this agent was for this patient group.
Cognitive impairment is among the many possible damaging outcomes of war captivity and PTSD. This study of 95 Israeli ex-POWs from the 1973 Yom Kippur War looked at the effects of physical and psychological suffering on cognitive performance many years after the traumatic experiences.
Comorbid psychiatric illness can negatively impact compliance with antiretroviral treatment (ART) in HIV-infected patients. This French study used data from a large national survey to determine if PTSD and poor adherence to ART were linked.
PTSD is more prevalent in women than in men, but is this because women's exposure to traumatic events is greater or because they are more vulnerable to traumatic events? This study looked at the question by drawing on nationally representative NESARC data and using a model including 19 types of traumatic events.
Suicidality is both common and understudied among trauma survivors. The authors of this study looked at suicide risk factors in 480 trauma survivors. This was the first suicide study to use DSM-5 PTSD symptoms and to analyze the relationship between benzodiazepines and suicide in trauma survivors with or without PTSD. Read the article to find out more.
In Arab countries, a substantial number of people suffering from the psychological and physical sequelae of trauma are seen in the primary care setting. But, what mental health resources are available to address these issues? The authors of this study conducted a needs assessment among psychiatrists and primary care physicians practicing in clinical settings in the Midddle East. Their findings may surprise you.
PTSD has a high comorbidity with other psychiatric disorders, including mood, substance use, personality, and panic disorders. It has demonstrated clinical antidepressant efficacy equivalent to SSRIs and may be an effective treatment for anxiety disorders and sleep disturbances. The objective of this study was to determine the efficacy, safety, and tolerability of vilazodone in the treatment of PTSD with comorbid mild-to-moderate depression.
Although exposure therapies are effective for PTSD, they require many sessions, and some patients still have residual symptoms. Methylene blue, an agent that enhances memory, has previously shown success in augmentation of exposure therapy for claustrophobia. Could it also be helpful in PTSD? See what this randomized controlled trial found.
In this study of adolescents exposed to the 2008 Wenchuan earthquake in China, Fan et al investigate the relationships between disturbed sleep and the development of depression and PTSD. The authors also make recommendations for assessing sleep-related symptoms in the wake of natural disasters.
Why are so many individuals with posttraumatic stress disorder receiving inadequate care? To probe for possible reasons, this study investigated treatments received and predictors of treatment utilization among patients at Massachusetts General Hospital who were diagnosed with primary PTSD.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”